Our mission is to change the world, one protein at a time. We founded Absci with
the goal of creating better medicines and helping them reach patients sooner. We
recognized the extraordinary medical and economic potential of protein-based
drugs (biologics), but also the significant challenges the biopharmaceutical
industry faces to both discover novel biologics and generate cell lines to
manufacture them at commercial scale. We looked at the end game getting better
medicines to patients, faster  and asked: how? We built our technology to be
that how.

We believe we are replacing the fragmented steps and inefficiencies of the
conventional biologic drug discovery and cell line development processes with
our fully integrated, end-to-end platform designed to create new and better
biologics and accelerate their advancement into clinical trials and ultimately
into the marketplace where they can serve patients. Combining innovative
approaches, including synthetic biology, high-throughput single-cell screening,
and deep learning artificial intelligence (AI), we seek to identify optimal drug
candidates by exploring expansive protein sequence solution spaces including
considering sequences that nature's evolutionary trajectory has yet to propose.
We believe our platform allows us to expand biological possibilities and
generate proteins intractable to produce with other technologies to ensure the
best drug candidates have the opportunity to become therapeutic realities for
patients. Our goal is to enable the creation of better medicines by Translating
Ideas into Drugs.

We were formed as AbSci, LLC in August 2011 as a limited liability company under
the Oregon Limited Liability Act and subsequently converted into a Delaware
limited liability company under the laws of the State of Delaware in April 2016.
In October 2020, we completed a reorganization whereby we converted from a
Delaware limited liability company to a Delaware corporation under the name
Absci Corporation. We have three direct wholly-owned subsidiaries, AbSci, LLC,
De Novo Design, LLC and Tar


Absci Corp

	Our mission is to change the world, one protein at a time. We founded Absci with the goal of creating better medicines and helping them reach patients sooner. We recognized the extraordinary medical and economic potential of protein-based drugs (biologics), but also the significant challenges the biopharmaceutical industry faces to both discover novel biologics and generate cell lines to manufacture them at commercial scale.

Should you buy, sell, or hold Absci Corp (ABSI) ?

Absci Corp (ABSI) : Buy or Sell